Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

Novartis and Ratio to progress next-gen radiotherapeutic

2
SHARES

The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.

radiotherapeutic radioligand Novartis

Novartis Pharma AG has agreed to a radiotherapeutic radioligand therapy-focused license and collaboration with Ratio Therapeutics. Through this deal, Ratio is eligible to receive milestone payments up to $745 million.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The collaboration will utilise Ratio’s expertise in radioligand therapy and its technology platforms for development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.

Advancing a next-generation radiotherapeutic therapy

“Ratio is honoured and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic,” commented Dr Jack Hoppin, PhD, Chief Executive Officer of Ratio. “Together, we aim to develop a best-in-class therapy in the fight against SSTR2-expressing tumours.”

Ratio is honoured and excited to partner with Novartis on the development of a next-generation SSTR2-targeting therapeutic”

Novartis will be responsible for all remaining development, manufacturing, and commercialisation. This new collaboration is set to further improve safety and efficacy of radiopharmaceuticals.

Radioligand therapy – potential in oncology

“We are delighted to collaborate with Ratio to advance this [radioligand therapy] candidate and work together to bring forward additional therapeutic options for patients with difficult-to-treat cancer,” stated Fiona Marshall, President of Biomedical Research at Novartis. “Radioligand therapies hold transformative potential for certain forms of cancer.”

In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.” For example, targeted radioligand therapy has shown promise for eligible patients with prostate cancer. The US Food and Drug Administration (FDA) approved Novartis’ Pluvicto™ (lutetiumlutetium Lu 177 vipivotide tetraxetan) in 2022.

In EPR’s 2023 article, Dr Hoppin and Dr Babich anticipated that future technological advancement “in particle acceleration will make isotopes readily available and will also bring down costs to further facilitate the feasibility of local radiopharmaceutical manufacturing”.

Share via
Share via